{"entity":{"id":"nct05955508","kind":"trial","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","aka":[],"tldr":"A phase 2 trial of Linvoseltamab in multiple myeloma, run by Regeneron Pharmaceuticals, active and no longer recruiting.","summary":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma is a phase 2 interventional study registered as NCT05955508 by Regeneron Pharmaceuticals, with 40 participants enrolled, started 2024-01-30 and due to reach its primary completion in 2033-01-25. Interventions recorded: Linvoseltamab. Conditions listed: Smoldering Multiple Myeloma (SMM). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05955508","url":"https://clinicaltrials.gov/study/NCT05955508"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["linvoseltamab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05955508","phase":"2","setting":"Phase 2 Study of Linvoseltamab in Patients With Smoldering Multiple Myeloma at High Risk of Progression to Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","enrolled":40,"outcomes":[]},"route":"/trials/nct05955508/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}